Small molecules inhibitors of plasminogen activator inhibitor-1-An overview

European Journal of Medicinal Chemistry

Volumn 92, Issue , 2015, Pages 619-636

  Rouch, Anne ^a,b   Vanucci Bacqué, Corinne ^a,b   Bedos Belval, Florence ^a,b   Baltas, Michel ^a,b  

^a CNRS   (France)

^b Université Paul Sabatier Toulouse III   (France)

Author keywords

Cardiovascular diseases; Fibrinolysis; Inhibitors; Plasminogen activator inhibitor (PAI 1); Tissue type plasminogen activator (tPA); Urokinase plasminogen activator (uPA)

Indexed keywords

AZETIDINE DERIVATIVE; BENZOFURAN DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; EMBELIN; FLUFENAMIC ACID; INDOLE DERIVATIVE; MENTHOL; OXADIAZOLE DERIVATIVE; OXADIAZOLIDINEDIONE; OXALAMIDE DERIVATIVE; OXAZOLIDINE DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERAZINEDIONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYPHENOL DERIVATIVE; PROTEIN INHIBITOR; PSEUDO PEPTIDE INHIBITOR; PYRROLIN 2 ONE DERIVATIVE; PYRROLINE DERIVATIVE; UNCLASSIFIED DRUG; MOLECULAR LIBRARY; SERPINE1 PROTEIN, HUMAN;

ALKYLATION; ALZHEIMER DISEASE; ARTERY THROMBOSIS; BETA SHEET; BINDING KINETICS; BINDING SITE; BLOOD CLOT LYSIS; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EUCALYPTUS; EUCALYPTUS ALBENS; EYE DISEASE; FLUORESCENCE SPECTROSCOPY; HUMAN; IC50; MOLECULAR DOCKING; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; REVIEW; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; VASCULAR DISEASE; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; SYNTHESIS;

HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMALL MOLECULE LIBRARIES;

EID: 84922309247     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.01.010     Document Type: Review

References (104)

1. D.M. Dupont, J.B. Madsen, T. Kristensen, J.S. Bodker, G.E. Blouse, P.A. Andreasen, Biochemical properties of plasminogen activator inhibitor-1, Front. Biosci. 14 (2009) 1337e1361, http://dx.doi.org/10.2741/3312.
2. C.M. Hekman, D.J. Loskutoff, Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants, J. Biol. Chem. 260 (1985) 11581e11587 doi:10/1985; 260(21):11581e7.
3. T. Urano, L. Strandberg, L.B. Johansson, T. Ny, A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate, Eur. J. Biochem. 209 (1992) 985e992, http://dx.doi.org/10.1111/j.1432-1033.1992.tb17372.x.
4. P.J. Declerck, M. De Mol, D.E. Vaughansq, D. Collen, Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a non-inhibitory substrate for tissue-type plasminogen activator, J. Biol. Chem. 267 (1992) 11693e11696.
5. M. Dewilde, S.V. Strelkov, A. Rabijns, P.J. Declerck, High quality structure of cleaved PAI-1-stab, J. Struct. Biol. 165 (2009) 126e132, http://dx.doi.org/10.1016/j.jsb.2008.11.001.
6. D.A. Lawrence, S. Palaniappan, S. Stefansson, S.T. Olson, M.A. Francis-Chmura, J.D. Shore, D. Ginsburg, Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis, J. Biol. Chem. 272 (1997) 7676e7680, http://dx.doi.org/10.1074/jbc.272.12.7676.
7. D. Seiffert, D.J. Loskutoff, Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin, J. Biol. Chem. 266 (1991) 2824e2830.
8. A. Zhou, J.A. Huntington, N.S. Pannu, R.W. Carrell, R.J. Read, How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration, Nat. Struct. Biol. 10 (2003) 541e544, http://dx.doi.org/10.1038/nsb943.
9. C.R. Schar, G.E. Blouse, K.H. Minor, C.B. Peterson, A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity, J. Biol. Chem. 283 (2008) 10297e10309, http://dx.doi.org/10.1074/jbc.M708017200.
10. D.A. Lawrence, M.B. Berkenpas, S. Palaniappan, D. Ginsburg, Localization of vitronectin binding domain in plasminogen activator inhibitor-1, J. Biol. Chem. 269 (1994) 15223e15228.
11. N.A. De Prada, F. Schroeck, E. Sinner, B. Muehlenweg, Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin. Characterization of different PAI-1 mutants, Eur. J. Biochem. 269 (2002) 184e192, http://dx.doi.org/10.1046/j.0014-2956.2002.02639.x.
12. M. Vanmeijer, H. Pannekoek, Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update, Fibrinolysis 9 (1995) 263e276, http://dx.doi.org/10.1016/S0268-9499(95)80015-8.
13. M.S. Pepper, Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis, Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1104e1117, http://dx.doi.org/10.1161/hq0701.093685.
14. P. Carmeliet, D. Collen, Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system, Thromb. Res. 91 (1998) 255e285, http://dx.doi.org/10.1016/S0049-3848(98)00122-4.
15. C. Oh, B. Ariue, R. Alban, B. Shaw, S. Cho, PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model, Biochem. Biophys. Res. Commun. 294 (2002) 1155e1160, http://dx.doi.org/10.1016/S0006-291X(02)00577-6.
16. S. Stefansson, D.A. Lawrence, The serpin PAI-1 inhibits cell migration by blocking integrin avb3 binding to vitronectin, Nature 383 (1996) 441e443, http://dx.doi.org/10.1038/383441a0.
17. C. Lee, T. Huang, Plasminogen activator inhibitor-1: the expression, biological functions, and effects on tumorigenesis and tumor cell adhesion and migration, J. Cancer Mol. 1 (2005) 25e36.
18. D.E. Vaughan, PAI-1 and cellular migration: dabbling in paradox, Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1522e1523, http://dx.doi.org/10.1161/01.ATV.0000037901.89736.0A.
19. H.C. Kwaan, A.P. Mazar, B.J. McMahon, The apparent uPA/PAI-1 paradox in cancer: more than meets the eye, Semin. Thromb. Haemost. 39 (2013) 382e391, http://dx.doi.org/10.1055/s-0033-1338127.
20. M.K.V. Durand, J.S. Bødker, A. Christensen, D.M. Dupont, M. Hansen, J.K. Jensen, S. Kjelgaard, L. Mathiasen, K.E. Pedersen, S. Skeldal, T. Wind, P.A. Andreasen, Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis, Thromb. Haemost. 91 (2004) 438e449, http://dx.doi.org/10.1160/TH03-12-0784.
21. L. Devy, S. Blacher, C. Grignet-Derbus, K. Bajou, V. Masson, R.D. Gerard, A. Gils, G. Carmeliet, P. Carmeliet, P.J. Declerck, A. Noel, J.-M. Foidart, The proor antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent, FASEB J. 16 (2002) 147e154.
22. V. Lambert, C. Munaut, P. Carmeliet, Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials, Investig. Ophthalmol. Vis. Sci. 44 (2003) 2791e2797.
23. Y. Ma, J.S. Ryu, A. Dulay, M. Segal, S. Guller, Regulation of plasminogen activator inhibitor (PAI)-1 expression in a human trophoblast cell line by glucocorticoid (GC) and transforming growth factor (TGF)-b, Placenta 23 (2002) 727e734, http://dx.doi.org/10.1053/plac.2002.0863.
24. S.M. Kutz, J. Hordines, P.J. Mckeown-Longo, P.J. Higgins, TGF-b 1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion, J. Cell Sci. 21 (2001) 3905e3914.
25. R. Westrick, D. Eitzman, Plasminogen activator inhibitor-1 in vascular thrombosis, Curr. Drug Targets 8 (2007) 966e1002.
26. Q. Wu, Z. Zhao, Inhibition of PAI-1: a new anti-thrombotic approach, Curr. Drug Targets. Cardiovasc. Haematol. Disord. 2 (2002) 27e42, http://dx.doi.org/10.2174/1568006023337727.
27. Y. Ji, T.L. Strawn, E.A. Grunz, M.J. Stevenson, A.W. Lohman, D.A. Lawrence, W.P. Fay, Multifaceted role of plasminogen activator inhibitor-1 in regulating early remodeling of vein bypass grafts, Arterioscler. Thromb. Vasc. Biol. 31 (2011) 1781e1787, http://dx.doi.org/10.1161/ATVBAHA.111.228767.
28. J. Wu, L. Peng, G.A. McMahon, D.A. Lawrence, W.P. Fay, Recombinant plasminogen activator inhibitor-1 inhibits intimal hyperplasia, Arterioscler. Thromb. Vasc. Biol. 29 (2009) 1565e1570, http://dx.doi.org/10.1161/ATVBAHA.109.189514.
29. D. Eitzman, R. Westrick, Z. Xu, Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery, Blood 96 (2000) 4212e4215.
30. J. Schneiderman, M.S. Sawdey, M.R. Keeton, G.M. Bordin, E.F. Bernstein, R.B. Dilley, D.J. Loskutoff, Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries, Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 6998e7002.
31. S. Kutz, C. Higgins, P. Higgins, Novel combinatorial therapeutic targeting of PAI-1 (SERPINE1) gene expression in alzheimer's disease, Mol. Med. Ther. 1 (2012) 1e6, http://dx.doi.org/10.4172/2324-8769.1000106.Novel.
32. B. De Taeye, L.H. Smith, D.E. Vaughan, Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease, Curr. Opin. Pharmacol. 5 (2005) 149e154, http://dx.doi.org/10.1016/j.coph.2005.01.007.
33. M.L.G. Correia, W.G. Haynes, A role for plasminogen activator inhibitor-1 in obesity: from pie to PAI? Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2183e2185, http://dx.doi.org/10.1161/01.ATV.0000244018.24120.70.
34. D.J. Schneider, B.E. Sobel, PAI-1 and diabetes: a journey from the bench to the bedside, Diabetes Care 35 (2012) 1961e1967, http://dx.doi.org/10.2337/dc12-0638.
35. C.J. Lyon, W.A. Hsueh, Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease, Am. J. Med. 115 (2003) 62e68, http://dx.doi.org/10.1016/j.amjmed.2003.08.014.
36. D.J. Loskutoff, J.P. Quigley, PAI-1, fibrosis, and the elusive provisional fibrin matrix, J. Clin. Investig. 106 (2000) 1441e1443.
37. A. Ghosh, D. Vaughan, PAI-1 in tissue fibrosis, J. Cell. Physiol. 227 (2012) 493e507, http://dx.doi.org/10.1002/jcp.22783.PAI-1.
38. N. Brown, Therapeutic potential of plasminogen activator inhibitor-1 inhibitors, Ther. Adv. Cardiovasc. Dis. 4 (2010) 315e324, http://dx.doi.org/10.1177/1753944710379126.
39. Y.M. Fortenberry, Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present), Expert Opin. Ther. Pat. 23 (2013) 801e815, http://dx.doi.org/10.1517/13543776.2013.782393.
40. A. Gils, P.J. Declerck, The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors, Thromb. Haemost. 91 (2004) 425e437, http://dx.doi.org/10.1160/TH03-12-0764.
41. J. Damare, S. Brandal, Y.M. Fortenberry, Inhibition of PAI-1 antiproteolytic activity against tPA by RNA aptamers, Nucleic Acid Ther. 24 (2014), http://dx.doi.org/10.1089/nat.2013.0475.
42. V.J. Marder, Inhibiting the inhibitor, Circulation 85 (1992) 386e387, http://dx.doi.org/10.1161/01.CIR.85.1.386.
43. B. Van De Craen, P.J. Declerck, A. Gils, The biochemistry, physiology and pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo, Thromb. Res. 130 (2012) 576e585, http://dx.doi.org/10.1016/j.thromres.2012.06.023.
44. D.T. Eitzman, W.P. Fay, D.A. Lawrence, A.M.M. Francis-Chmura, J.D. Shore, S.T. Olson, D. Ginsburg, Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro, J. Clin. Investig. 95 (1995) 2416e2420, http://dx.doi.org/10.1172/JCI117937.
45. Y. Xue, P. Bjorquist, T. Inghardt, M. Linschoten, D. Musil, L. Sjolin, J. Deinum, Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide, Structure 6 (1998) 627e636, http://dx.doi.org/10.1016/S0969-2126(98)00064-1.
46. S. D'Amico, J.A. Martial, I. Struman, A peptide mimicking the C-terminal part of the reactive center loop induces the transition to the latent form of plasminogen activator inhibitor type-1, FEBS Lett. 586 (2012) 686e692, http://dx.doi.org/10.1016/j.febslet.2012.02.013.
47. N. Hirayama, K. Kurokawa, T. Miyata, N. Yamaoka, Plasminogen activator inhibitor-1 inhibitor, WO2007083689 A1 (2007).
48. Y. Izuhara, S. Takahashi, M. Nangaku, S. Takizawa, H. Ishida, K. Kurokawa, C. van Ypersele de Strihou, N. Hirayama, T. Miyata, Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis, Arterioscler. Thromb. Vasc. Biol. 28 (2008) 672e677, http://dx.doi.org/10.1161/ATVBAHA.107.157479.
49. N. Yamaoka, Y. Kawano, Y. Izuhara, T. Miyata, K. Meguro, Structureeactivity relationships of new 2-acylamino-3-thiophenecarboxylic acid dimers as plasminogen activator inhibitor-1 inhibitors, Chem. Pharm. Bull. (Tokyo) 58 (2010) 615e619, http://dx.doi.org/10.1248/cpb.58.615.
50. N. Yamaoka, H. Kodama, Y. Izuhara, T. Miyata, K. Meguro, Structureeactivity relationships of new N-acylanthranilic acid derivatives as plasminogen activator inhibitor-1 inhibitors, Chem. Pharm. Bull. (Tokyo) 59 (2011) 215e224, http://dx.doi.org/10.1248/cpb.59.215.
51. Y. Izuhara, N. Yamaoka, H. Kodama, T. Dan, S. Takizawa, N. Hirayama, K. Meguro, C. van Ypersele de Strihou, T. Miyata, A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates, J. Cereb. Blood Flow Metab. 30 (2010) 904e912, http://dx.doi.org/10.1038/jcbfm.2009.272.
52. J. Bryans, P. Charlton, I. Chicarelli-Robinson, M. Collins, R. Faint, C. Latham, I. Shaw, S. Trew, Inhibition of plasminogen activator inhibitor-1 activity by two diketopiperazines, XR330 and XR334 produced by streptomyces sp, J. Antibiot. (Tokyo) 49 (1996) 1014e1021.
53. P. Charlton, R. Faint, F. Bent, J. Bryans, I. Chicarelli-Robinson, I. Mackie, S. Machin, P. Bevan, Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity, Thromb. Haemost. 75 (1996) 808e815.
54. P. Charlton, R. Faint, C. Barnes, F. Bent, A. Folkes, D. Templeton, I. Mackie, S. Machin, P. Bevan, XR5118, a novel modulator of plasminogen activator inhibitor-1 (PAI-1), increases endogenous tPA activity in the rat, Fibrinolysis Proteolysis 11 (1997) 51e56, http://dx.doi.org/10.1016/S0268-9499(97) 80009-4.
55. A.P. Einholm, K.E. Pedersen, T. Wind, P. Kulig, M.T. Overgaard, J.K. Jensen, J.S. Bødker, A. Christensen, P. Charlton, P.A. Andreasen, Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1, Biochem. J. 373 (2003) 723e732, http://dx.doi.org/10.1042/BJ20021880.
56. A. Folkes, M.B. Roe, S. Sohal, J. Golec, R. Faint, T. Brooks, P. Charlton, Synthesis and in vitro evaluation of a series of diketopiperazine inhibitors of plasminogen activator inhibitor-1, Bioorg. Med. Chem. Lett. 11 (2001) 2589e2592, http://dx.doi.org/10.1016/S0960-894X(01)00508-X.
57. A. Folkes, S.D. Brown, L.E. Canne, J. Chan, E. Engelhardt, S. Epshteyn, R. Faint, J. Golec, A. Hanel, P. Kearney, J.W. Leahy, M. Mac, D. Matthews, M.P. Prisbylla, J. Sanderson, R.J. Simon, Z. Tesfai, N. Vicker, S. Wang, R.R. Webb, P. Charlton, Design, synthesis and in vitro evaluation of potent, novel, small molecule inhibitors of plasminogen activator inhibitor-1, Bioorg. Med. Chem. Lett. 12 (2002) 1063e1066, http://dx.doi.org/10.1016/S0960-894X(02)00078-1.
58. S. Wang, J. Golec, W. Miller, S. Milutinovic, A. Folkes, S. Williams, T. Brooks, K. Hardman, P. Charlton, S. Wren, J. Spencer, Novel inhibitors of plasminogen activator inhibitor-1: development of new templates from diketopiperazines, Bioorg. Med. Chem. Lett. 12 (2002) 2367e2370, http://dx.doi.org/10.1016/S0960-894X(02)00389-X.
59. T. Brooks, S. Wang, N. Brünner, P. Charlton, XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro, Anticancer Drugs 15 (2004) 37e44, http://dx.doi.org/10.1097/00001813-200401000-00007.
60. P. Bj?orquist, J. Ehnebom, T. Inghardt, L. Hansson, M. Lindberg, M. Linschoten, M. Str?omqvist, J. Deinum, Identification of the binding site for a lowmolecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis, Biochemistry 37 (1998) 1227e1234, http://dx.doi.org/10.1021/bi971554q.
61. R. Egelund, A.P. Einholm, K.E. Pedersen, R.W. Nielsen, A. Christensen, J. Deinum, P.A. Andreasen, A regulatory hydrophobic area in the flexible joint region of plasminogen activator inhibitor-1, defined with fluorescent activity-neutralizing ligands: ligand-induced serpin polymerization, J. Biol. Chem. 276 (2001) 13077e13086, http://dx.doi.org/10.1074/jbc.M009024200.
62. D.L. Crandall, J.K. Hennan, H. Elokdah, G. Krishnamurthy, T.M. Antrilli, J.S. Bauer, G.A. Morgan, R.E. Swillo, WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation, Biochem. Biophys. Res. Commun. 311 (2003) 904e908, http://dx.doi.org/10.1016/j.bbrc.2003.10.088.
63. D. Crandall, H. Elokdah, L. Di, J.K. Hennan, N.V. Gorlatova, D.A. Lawrence, Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy, J. Thromb. Haemost. 2 (2004) 1422e1428, http://dx.doi.org/10.1111/j.1538-7836.2004.00829.x.
64. A. Gils, J.-M. Stassen, H. Nar, J.T. Kley, W. Wienen, U.J. Ries, P.J. Declerck, Characterization and comparative evaluation of a novel PAI-1 inhibitor, Thromb. Haemost. 88 (2002) 137e143, http://dx.doi.org/10.1111/j.1538-7836.2004.00829.x.
65. H. Lassman, J. Wilker, V. Anderson, M. Agnew, R. Allen, W. Novick, Fendosal (HP 129): a potent anti-inflammatory and analgesic compound, Agents Actions 8 (1978) 209e217, http://dx.doi.org/10.1007/BF01966606.
66. R. Slade, Y. Klimova, R. Halter, Compounds for Alzheimer's disease, WO2006041874 (2010).
67. A. Cark, D. Fleenor, PAI-1 Expression and Activity Inhibitors for the Treatment of ocular disorders, WO2009131850A2 (2009).
68. V.B. Anderson, M.N. Agnew, R.C. Allen, Carboxyarylindoles as nonsteroidal antiinflammatory agents, J. Med. Chem. 19 (1976) 318e325, http://dx.doi.org/10.1021/jm00224a023.
69. H. Elokdah, M. Abou-Gharbia, J.K. Hennan, G. McFarlane, C.P. Mugford, G. Krishnamurthy, D.L. Crandall, Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization, J. Med. Chem. 47 (2004) 3491e3494, http://dx.doi.org/10.1021/jm049766q.
70. Heart disease and stroke, more than 300 medicines in testing for two leading causes of death in americans, Med. Dev. Hear. Dis. Stroke 1 (2009) 1e31. http://www.phrma.org/sites/default/files/pdf/heart-2009.pdf.
71. N.V. Gorlatova, J.M. Cale, H. Elokdah, D. Li, K. Fan, M. Warnock, D.L. Crandall, D.A. Lawrence, Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor, J. Biol. Chem. 282 (2007) 9288e9296, http://dx.doi.org/10.1074/jbc.M611642200.
72. B. Hu, J.W. Jetter, J.E. Wrobel, T.M. Antrilli, J.S. Bauer, L. Di, S. Polakowski, U. Jain, D.L. Crandall, Synthesis and SAR of 2-carboxylic acid indoles as inhibitors of plasminogen activator inhibitor-1, Bioorg. Med. Chem. Lett. 15 (2005) 3514e3518, http://dx.doi.org/10.1016/j.bmcl.2005.05.095.
73. S.J. Gardell, J.A. Krueger, T.A. Antrilli, H. Elokdah, S. Mayer, S.J. Orcutt, D.L. Crandall, G.P. Vlasuk, Neutralization of plasminogen activator inhibitor I (PAI-1) by the synthetic antagonist PAI-749 via a dual mechanism of action, Mol. Pharmacol. 72 (2007) 897e906, http://dx.doi.org/10.1124/mol.107.037010.protease.
74. V. Dragan, J. Potoski, W. McMahon, J. Helom, X. Shi, Processes and compounds for the preparation of substituted naphthylindole derivatives, US 20080071091 A1 (2007).
75. A.J. Lucking, A. Visvanathan, H. Philippou, S. Fraser, P.J. Grant, T.M. Connolly, S.J. Gardell, G.Z. Feuerstein, K.A.A. Fox, N.A. Booth, D.E. Newby, Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of fibrinolysis, J. Thromb. Haemost. 8 (2010) 1333e1339, http://dx.doi.org/10.1111/j.1538-7836.2010.03872.x.
76. J.S. Jacobsen, T.A. Comery, R.L. Martone, H. Elokdah, D.L. Crandall, A. Oganesian, S. Aschmies, Y. Kirksey, C. Gonzales, J. Xu, H. Zhou, K. Atchison, E. Wagner, M.M. Zaleska, I. Das, R.L. Arias, J. Bard, D. Riddell, S.J. Gardell, et al., Enhanced clearance of Ab in brain by sustaining the plasmin proteolysis cascade, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 8754e8759, http://dx.doi.org/10.1073/pnas.0710823105.
77. http://clinicaltrials.gov/show/NCT00366288No, (n.d.).
78. G. De Nanteuil, C. Lila-Ambroise, A. Rupin, M.-O. Vallez, T.J. Verbeuren, New fibrinolytic agents: benzothiophene derivatives as inhibitors of the t-PA-PAI-1 complex formation, Bioorg. Med. Chem. Lett. 13 (2003) 1705e1708, http://dx.doi.org/10.1016/S0960-894X(03)00233-6.
79. A. Rupin, R. Gaertner, P. Mennecier, I. Richard, A. Benoist, G. De Nanteuil, T.J. Verbeuren, S35225 is a direct inhibitor of plasminogen activator inhibitor type-1 activity in the blood, Thromb. Res. 122 (2008) 265e270, http://dx.doi.org/10.1016/j.thromres.2007.11.006.
80. B. Ye, S. Bauer, B.O. Buckman, A. Ghannam, B.D. Griedel, S.-K. Khim, W. Lee, K.L. Sacchi, K.J. Shaw, A. Liang, Q. Wu, Z. Zhao, Synthesis and biological evaluation of menthol-based derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1), Bioorg. Med. Chem. Lett. 13 (2003) 3361e3365, http://dx.doi.org/10.1016/S0960-894X(03)00686-3.
81. A. Liang, F. Wu, K. Tran, S.W. Jones, G. Deng, B. Ye, Z. Zhao, R.M. Snider, W.P. Dole, J. Morser, Q. Wu, Z. Zhao, Characterization of a small molecule PAI-1 inhibitor, ZK4044, Thromb. Res. 115 (2005) 341e350, http://dx.doi.org/10.1016/j.thromres.2004.09.021.
82. B. Ye, Y.-L. Chou, R. Karanjawala, W. Lee, S.-F. Lu, K.J. Shaw, S. Jones, D. Lentz, A. Liang, J.-L. Tseng, Q. Wu, Z. Zhao, Synthesis and biological evaluation of piperazine-based derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1), Bioorg. Med. Chem. Lett. 14 (2004) 761e765, http://dx.doi.org/10.1016/j.bmcl.2003.11.035.
83. V. Pandya, M. Jain, G. Chakrabarti, H. Soni, B. Parmar, B. Chaugule, J. Patel, J. Joshi, N. Joshi, A. Rath, M. Raviya, M. Shaikh, K.V.V.M. Sairam, H. Patel, P. Patel, Discovery of inhibitors of plasminogen activator inhibitor-1: structureeactivity study of 5-nitro-2-phenoxybenzoic acid derivatives, Bioorg. Med. Chem. Lett. 21 (2011) 5701e5706, http://dx.doi.org/10.1016/j.bmcl.2011.08.031.
84. A. Gopalsamy, S.L. Kincaid, J.W. Ellingboe, T.M. Groeling, T.M. Antrilli, G. Krishnamurthy, A. Aulabaugh, G.S. Friedrichs, D.L. Crandall, Design and synthesis of oxadiazolidinediones as inhibitors of plasminogen activator inhibitor-1, Bioorg. Med. Chem. Lett. 14 (2004) 3477e3480, http://dx.doi.org/10.1016/j.bmcl.2004.04.058.
85. M.R. Jain, S. Shetty, G. Chakrabarti, V. Pandya, A. Sharma, B. Parmar, S. Srivastava, M. Raviya, H. Soni, P.R. Patel, In vitro PAI-1 inhibitory activity of oxalamide derivatives, Eur. J. Med. Chem. 43 (2008) 880e884, http://dx.doi.org/10.1016/j.ejmech.2007.05.011.
86. H. Miyazaki, T. Ogiku, H. Sai, Y. Moritani, A. Ohtani, H. Ohmizu, Synthesis and evaluation of pyrrolin-2-one compounds, a series of plasminogen activator inhibitor-1 inhibitors, Chem. Pharm. Bull. (Tokyo) 57 (2009) 979e985, http://dx.doi.org/10.1248/cpb.57.979.
87. H. Miyazaki, T. Miyake, Y. Terakawa, H. Ohmizu, T. Ogiku, A. Ohtani, Evaluation of pyrrolin-2-one derivatives synthesized by a new practical method as inhibitors of plasminogen activator inhibitor-1 (PAI-1), Bioorg. Med. Chem. Lett. 20 (2010) 546e548, http://dx.doi.org/10.1016/j.bmcl.2009.11.102.
88. J. Neve, P. de Almeida Leone, A.R. Carroll, R.W. Moni, N.J. Paczkowski, G. Pierens, P. Bj?orquist, J. Deinum, J. Ehnebom, T. Inghardt, G. Guymer, P. Grimshaw, R.J. Quinn, Sideroxylonal C, a new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of Eucalyptus albens, J. Nat. Prod. 62 (2011) 324e326, http://dx.doi.org/10.1021/np980286\+.
89. J.M. Cale, S.-H. Li, M. Warnock, E.J. Su, P.R. North, K.L. Sanders, M.M. Puscau, C.D. Emal, D.A. Lawrence, Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1, J. Biol. Chem. 285 (2010) 7892e7902, http://dx.doi.org/10.1074/jbc.M109.067967.
90. X. Chen, J.A. Beutler, T.G. McCloud, A. Loehfelm, L. Yang, H. Dong, O.Y. Chertov, R. Salcedo, J.J. Oppenheim, O.M. Howard, Tannic acid is an inhibitor of CXCL12 (SDF-1 a)/CXCR4 with antiangiogenic activity, Clin. Cancer Res. 9 (2003) 3115e3123.
91. X. Liu, J. Kim, Y. Li, J. Li, F. Liu, X. Chen, Tannic acid stimulates glucose transport and inhibits adipocyte differentiation in 3T3-L1 cells 1, J. Nutr. 135 (2005) 165e171.
92. M. Nakai, Y. Fukui, S. Asami, Y. Toyoda-Ono, T. Iwashita, H. Shibata, T. Mitsunaga, F. Hashimoto, Y. Kiso, Inhibitory effects of oolong tea polyphenols on pancreatic lipase in vitro, J. Agric. Food Chem. 53 (2005) 4593e4598, http://dx.doi.org/10.1021/jf047814\+.
93. S.-H. Lia, A.A. Reinke, K.L. Sanders, C.D. Emal, J.C. Whisstock, J.A. Stuckey, D.A. Lawrence, Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1, Proc. Natl. Acad. Sci. U. S. A. 110 (2013) 4941e4949, http://dx.doi.org/10.1073/pnas.1216499110.
94. N.C. El-Ayache, S.-H. Li, M. Warnock, D.A. Lawrence, C.D. Emal, Novel bisarylsulfonamides and aryl sulfonimides as inactivators of plasminogen activator inhibitor-1 (PAI-1), Bioorg. Med. Chem. Lett. 20 (2010) 966e970, http://dx.doi.org/10.1016/j.bmcl.2009.12.051.
95. J. Jankun, M. Skotnicka, W. Łysiak-Szydłowska, A. Al-Senaidy, E. Skrzypczak-Jankun, Diverse inhibition of plasminogen activator inhibitor type 1 by theaflavins of black tea, Int. J. Mol. Med. 27 (2011) 525e529, http://dx.doi.org/10.3892/ijmm.2011.615.
96. J.-I. Suzuki, M. Ogawa, S. Muto, A. Itai, Y. Hirata, Mitsuaki Isobe, R. Nagai, Effects of specific chemical suppressors of plasminogen activator inhibitor-1 in cardiovascular diseases, Expert Opin. Investig. Drugs 20 (2011) 255e264, http://dx.doi.org/10.1517/13543784.2011.546784.
97. O. Fjellstrom, J. Deinum, T. Sjogren, C. Johansson, S. Geschwindner, V. Nerme, A. Legnehed, J. McPheat, K. Olsson, C. Bodin, A. Paunovic, D. Gustafsson, Characterization of a small molecule inhibitor of plasminogen activator inhibitor type 1 that accelerates the transition into the latent conformation, J. Biol. Chem. 288 (2012) 873e895, http://dx.doi.org/10.1074/jbc.M112.371732.
98. Z. Lin, J. Jensen, Z. Hong, X. Shi, L. Hu, P.A. Andreasen, M. Huang, Structural insight into inactivation of plasminogen activator inhibitor-1 by a smallmolecule antagonist, Chem. Biol. 20 (2013) 253e261, http://dx.doi.org/10.1016/j.chembiol.2013.01.002.
99. O. Gupta, M. Ali, G. Ray, C. Atal, Some pharmacological investigations of embelin and its semisynthetic derivatives, Indian J. Physiol. Pharmacol. 21 (1976) 31e39.
100. M. Yamaguti, K. Asano, J. Pharm. Soc. Jpn. 60 (1940) 585.
101. L.F. Fieser, E.M. Chambrel, Synthesis of embelin, rapanone and related quinones, J. Am. Chem. Soc. 70 (1948) 71e75.
102. F. Chen, G. Zhang, Z. Hong, Z. Lin, M. Lei, M. Huang, L. Hu, Design, synthesis, and SAR of embelin analogues as the inhibitors of PAI-1 (plasminogen activator inhibitor-1), Bioorg. Med. Chem. Lett. 24 (2014) 2379e2382, http://dx.doi.org/10.1016/j.bmcl.2014.03.045.
103. P. Carmeliet, L. Kieckens, L. Schoonjans, T.B. Ream, A. Van Nuffelen, G. Prendergast, M. Cole, R. Bronson, D. Collen, R.C. Mulligan, Plasminogen activator inhibitor-1 gene-deficient mice, J. Clin. Investig. 92 (1993) 2746e2755.
104. L. Erickson, G. Fici, J. Lund, T. Boyle, H.G. Polites, K.R. Marotti, Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene, Nature 346 (1990) 74e76, http://dx.doi.org/10.1038/346074a0.